Latest Clinical Trials News

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

BPH Energy’s June quarter update highlights ongoing legal proceedings over the PEP-11 permit, promising progress in AI-driven brain monitoring technology, and strategic moves toward hydrogen production facilities, supported by a robust cash reserve.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.

Alterity Therapeutics has reported encouraging topline results from its open-label Phase 2 trial of ATH434 in advanced Multiple System Atrophy, showing slowed disease progression and biomarker stabilization.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.